In brief: Prima, SciGen, Sonic
Thursday, 30 June, 2005
The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
SciGen (ASX:SIE) managing director and CEO Mark Compton will leave the company on August 5. While he will remain as CEO till then, he has resigned as a director, effective June 29. SciGen is searching for a new CEO who is likely to be based in Asia.
Former CEO and executive director of the Melbourne Pathology Group, Lou Panaccio has joined the board of Sonic Healthcare (ASX:SHL) as a non-executive director. He will also replace Colin Jackson as a member of the Audit Committee.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
